Comparison of Patients With Familial Chylomicronemia Syndrome and Multifactorial Chylomicronemia Syndrome
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgae613 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Catherine M Spagnuolo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada, N6A 5B7. Hauptthemen laut MEDLINE: Hyperlipoproteinemia Type I. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Context
Patients with rare familial chylomicronemia syndrome (FCS) and relatively common multifactorial chylomicronemia syndrome (MCS) both express severe hypertriglyceridemia, defined as plasma triglyceride concentration ≥10 mmol/L (≥885 mg/dL). Clinically there can be confusion between the 2 conditions.
Objective
To compare clinical and biochemical phenotypes in patients with genotypically characterized FCS and MCS.
Methods
We performed targeted sequencing of DNA from 193 patients with severe hypertriglyceridemia, classified them as having either FCS or MCS, and compared clinical and biochemical characteristics.
Results
Patients with FCS were significantly younger than patients with MCS (31.4 ± 16.7 vs 51.0 ± 11.3 years; P = .003), with earlier age at symptom onset (15.0 ± 15.8 vs 37.8 ± 8.8 years; P = .00066), lower body mass index (23.3 ± 3.1 vs 30.7 ± 5.0 kg/m2; P = .000016), and higher prevalence of pancreatitis events (81.8% vs 35.2%; P = .003). Furthermore, patients with FCS had a higher ratio of triglyceride to total cholesterol (ie, 4.18 ± 0.92 vs 1.08 ± 0.51; P < .0001) and lower plasma apolipoprotein B (ie, 0.56 ± 0.15 vs 1.02 ± 0.43 g/L; P < .0001) than patients with MCS. Patients with MCS with heterozygous pathogenic variants had a relatively more severe clinical presentation than other MCS genetic subgroups.
Conclusion
Patients with FCS have notable phenotypic differences from patients with MCS, although there is overlap. While genetic analysis of patients with persistent severe hypertriglyceridemia can definitively diagnose FCS, 8.8% of patients with MCS with sustained refractory hypertriglyceridemia behave functionally as if they have FCS, which should influence their eligibility for novel therapies for severe hypertriglyceridemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada, N6A 5B7.
- Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada, N6A 5B7.
ORCID-Profile: Robert A Hegele
Zitieren
APA
Spagnuolo, C. M., Wang, J., McIntyre, A. D., Kennedy, B. A., & Hegele, R. A. (2025). Comparison of Patients With Familial Chylomicronemia Syndrome and Multifactorial Chylomicronemia Syndrome. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae613
Vancouver
Spagnuolo CM, Wang J, McIntyre AD, Kennedy BA, Hegele RA. Comparison of Patients With Familial Chylomicronemia Syndrome and Multifactorial Chylomicronemia Syndrome. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae613
BibTeX
@article{Spagnuolo2025,
author = {Spagnuolo, Catherine M and Wang, Jian and McIntyre, Adam D and Kennedy, Brooke A and Hegele, Robert A},
title = {Comparison of Patients With Familial Chylomicronemia Syndrome and Multifactorial Chylomicronemia Syndrome},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgae613}
}
EUVIMED